Fernando C Fervenza

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7158309/publications.pdf

Version: 2024-02-01

182	14,581	28274	21540
papers	citations	55 h-index	114 g-index

186	186	186	8719
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis. Nephrology Dialysis Transplantation, 2022, 37, 1710-1721.	0.7	25
2	Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. American Journal of Kidney Diseases, 2022, 79, 570-581.	1.9	15
3	Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte Î²3 Integrin. Kidney International Reports, 2022, 7, 68-77.	0.8	10
4	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. Journal of the American Society of Nephrology: JASN, 2022, 33, 291-303.	6.1	10
5	â€œPresumedâ€•Primary Focal Segmental Glomerulosclerosis: A Novel Nuance for Steroid Therapy. Kidney International Reports, 2022, 7, 9-12.	0.8	2
6	Hematopoietic Stem Cell Transplant-Membranous Nephropathy Is Associated with Protocadherin FAT1. Journal of the American Society of Nephrology: JASN, 2022, 33, 1033-1044.	6.1	47
7	Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy. Drugs, 2022, 82, 109-132.	10.9	13
8	A Core Outcome Set for Trials in Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 53-64.	4.5	4
9	Kidney Histopathology in ANCA-Associated Vasculitides Treated with Plasma Exchange. Journal of the American Society of Nephrology: JASN, 2022, 33, 1223-1224.	6.1	5
10	Acute glomerulonephritis. Lancet, The, 2022, 399, 1646-1663.	13.7	24
11	Atypical Antiglomerular Basement Membrane Nephritis Following Immune Checkpoint Inhibitor. Kidney International Reports, 2022, 7, 1913-1916.	0.8	6
12	Complement Gene Variant Effect on Relapse of Complement-Mediated Thrombotic Microangiopathy after Eculizumab Cessation. Blood Advances, 2022, , .	5.2	2
13	The characteristics of seronegative and seropositive non-hepatitis-associated cryoglobulinemic glomerulonephritis. Kidney International, 2022, 102, 382-394.	5.2	6
14	Molecular Characterization of Membranous Nephropathy: Quo Vadis?. Journal of the American Society of Nephrology: JASN, 2022, 33, 1057-1059.	6.1	0
15	Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 994-1007.	4.5	13
16	Comparison of treatment options in adults with frequently relapsing or steroid-dependent minimal change disease. Nephrology Dialysis Transplantation, 2021, 36, 1821-1827.	0.7	5
17	Treatment of fibrillary glomerulonephritis with rituximab: a 12-month pilot study. Nephrology Dialysis Transplantation, 2021, 36, 104-110.	0.7	12
18	PEXIVAS. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 307-309.	4.5	6

#	Article	IF	Citations
19	The association of microhematuria with mesangial hypercellularity, endocapillary hypercellularity, crescent score and renal outcomes in immunoglobulin A nephropathy. Nephrology Dialysis Transplantation, 2021, 36, 840-847.	0.7	18
20	A Target Antigenâ€“Based Approach to the Classification of Membranous Nephropathy. Mayo Clinic Proceedings, 2021, 96, 577-591.	3.0	45
21	Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits. Journal of the American Society of Nephrology: JASN, 2021, 32, 1163-1173.	6.1	33
22	APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis. Pediatric Nephrology, 2021, 36, 2747-2757.	1.7	3
23	Limited Significance of Antifactor H Antibodies in Patients with Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 939-941.	4.5	4
24	Immune-Complex Glomerulonephritis After COVID-19 Infection. Kidney International Reports, 2021, 6, 1170-1173.	0.8	19
25	Protocadherin 7â€“Associated Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2021, 32, 1249-1261.	6.1	92
26	Therapeutic trials in adult FSGS: lessons learned and the road forward. Nature Reviews Nephrology, 2021, 17, 619-630.	9.6	53
27	COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab. Nephrology Dialysis Transplantation, 2021, 36, 1758-1760.	0.7	11
28	Genomics Integration Into Nephrology Practice. Kidney Medicine, 2021, 3, 785-798.	2.0	13
29	Crystal-Induced Podocytopathy Producing Collapsing Focal Segmental Glomerulosclerosis in Monoclonal Gammopathy of Renal Significance: A Case Report. Kidney Medicine, 2021, 3, 659-664.	2.0	3
30	1H Nuclear Magnetic Resonance Spectroscopy-Based Methods for the Quantification of Proteins in Urine. Analytical Chemistry, 2021, 93, 13177-13186.	6.5	2
31	Identification of Genetic Causes of Focal Segmental Glomerulosclerosis Increases With Proper Patient Selection. Mayo Clinic Proceedings, 2021, 96, 2342-2353.	3.0	20
32	Membranous nephropathy. Nature Reviews Disease Primers, 2021, 7, 69.	30.5	167
33	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International, 2021, 100, S1-S276.	5.2	782
34	Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney International, 2021, 100, 753-779.	5.2	325
35	Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease. Kidney International, 2021, 100, 881-893.	5.2	7
36	Collagen IVÎ±345 dysfunction in glomerular basement membrane diseases. I. Discovery of a COL4A3 variant in familial Goodpastureâ€™s and Alport diseases. Journal of Biological Chemistry, 2021, 296, 100590.	3.4	19

#	Article	IF	Citations
37	In Patients with Membranous Lupus Nephritis, Exostosin-Positivity and Exostosin-Negativity Represent Two Different Phenotypes. Journal of the American Society of Nephrology: JASN, 2021, 32, 695-706.	6.1	56
38	Plasma exchange for the management of ANCA-associated vasculitis: the con position. Nephrology Dialysis Transplantation, 2021, 36, 231-236.	0.7	12
39	Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis. JCI Insight, 2021, 6, .	5.0	7
40	COVID-19 Vaccination and Glomerulonephritis. Kidney International Reports, 2021, 6, 2969-2978.	0.8	135
41	A focus group study of self-management in patients with glomerular disease.. Kidney International Reports, 2021, 7, 56-67.	0.8	2
42	Noninvasive Diagnosis of PLA2R-Associated Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1833-1839.	4.5	27
43	Neural epidermal growth factor-like 1 proteinÂ(NELL-1) associated membranous nephropathy. Kidney International, 2020, 97, 163-174.	5.2	213
44	An Open-Label Pilot Study ofÂAdrenocorticotrophic Hormone inÂtheÂTreatment of IgA Nephropathy atÂHigh Risk of Progression. Kidney International Reports, 2020, 5, 58-65.	0.8	17
45	Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study. Kidney International Reports, 2020, 5, 1679-1689.	0.8	17
46	Kidney Biopsy Is Required for Nephrotic Syndrome with PLA2R+ and Normal Kidney Function: The Con View. Kidney360, 2020, 1, 890-893.	2.1	7
47	Rate and Predictors of Finding Monoclonal Gammopathy of Renal Significance (MGRS) Lesions on Kidney Biopsy in Patients with Monoclonal Gammopathy. Journal of the American Society of Nephrology: JASN, 2020, 31, 2400-2411.	6.1	33
48	Nail-patella-like renal disease masquerading as Fabry disease on kidney biopsy: a case report. BMC Nephrology, 2020, 21, 341.	1.8	6
49	Nonrecurrent Early Post-Transplantation Focal Segmental Glomerulosclerosis. Kidney International Reports, 2020, 5, 1518-1525.	0.8	0
50	The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network. CKJ: Clinical Kidney Journal, 2020, 13, 597-606.	2.9	14
51	Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis with Severe Kidney Disease. Journal of the American Society of Nephrology: JASN, 2020, 31, 2688-2704.	6.1	48
52	Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 673-684.	4.5	66
53	The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nature Communications, 2020, 11, 1600.	12.8	120
54	Semaphorin 3Bâ€“associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. Kidney International, 2020, 98, 1253-1264.	5.2	138

#	Article	IF	Citations
55	Proteomic Analysis of Complement Proteins in Membranous Nephropathy. Kidney International Reports, 2020, 5, 618-626.	0.8	51
56	Successful Treatment of Patients With Refractory PLA2R-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases. American Journal of Kidney Diseases, 2020, 76, 883-888.	1.9	45
57	Standardized reporting of monoclonal immunoglobulinâ€“associated renal diseases: recommendations from a Mayo Clinic/Renal Pathology Society Working Group. Kidney International, 2020, 98, 310-313.	5.2	7
58	Recurrence of DNAJB9-Positive Fibrillary Glomerulonephritis After Kidney Transplantation: A Case Series. American Journal of Kidney Diseases, 2020, 76, 500-510.	1.9	13
59	Primary Nephrotic Syndrome. Nephrology Self-assessment Program: NephSAP, 2020, 19, 68-76.	3.0	0
60	Determination of Relapse Risk By Complement Gene Variants after Eculizumab Discontinuation in Complement-Mediated Thrombotic Microangiopathy: A Retrospective Review. Blood, 2020, 136, 25-26.	1.4	1
61	A Single-Center Phase 2 Open-Label Trial Evaluating the Safety and Efficacy of Daratumumab in Treatment of Patients with Monoclonal Gammopathy of Renal Significance. Blood, 2020, 136, 43-44.	1.4	0
62	Standardized classification and reporting of glomerulonephritis. Nephrology Dialysis Transplantation, 2019, 34, 193-199.	0.7	78
63	Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort. Nephrology Dialysis Transplantation, 2019, 34, 1508-1517.	0.7	46
64	Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. New England Journal of Medicine, 2019, 381, 36-46.	27.0	324
65	Noninvasive Urinary Monitoring of Progression in IgA Nephropathy. International Journal of Molecular Sciences, 2019, 20, 4463.	4.1	8
66	Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptorÂantibodies. Kidney International, 2019, 95, 429-438.	5.2	123
67	Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2019, 71, 1888-1893.	5.6	25
68	Standardized Outcomes in Nephrologyâ€”Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease. Kidney International, 2019, 95, 1280-1283.	5.2	20
69	Exostosin 1/Exostosin 2â€“Associated Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2019, 30, 1123-1136.	6.1	198
70	Editorial: a new era in anti-neutrophil cytoplasmic antibody vasculitis. Nephrology Dialysis Transplantation, 2019, 34, 379-381.	0.7	0
71	Health-related quality of life in glomerular disease. Kidney International, 2019, 95, 1209-1224.	5.2	38
72	Open-Label Clinical Trials of Oral Pulse Dexamethasone for Adults with Idiopathic Nephrotic Syndrome. American Journal of Nephrology, 2019, 49, 377-385.	3.1	3

#	Article	IF	Citations
73	C3 Glomerulonephritis: A Rare Etiology of the Pulmonary Renal Syndrome. Kidney Medicine, 2019, 1, 36-39.	2.0	0
74	Serum levels of DNAJB9 are elevated in fibrillaryÂglomerulonephritis patients. Kidney International, 2019, 95, 1269-1272.	5.2	26
75	Renal biopsy findings in patients with extreme obesity: more heterogeneous than youÂthink. Kidney International, 2019, 95, 495-498.	5.2	2
76	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 268-280.	5.2	198
77	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 281-295.	5.2	135
78	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes and Endocrinology,the, 2019, 7, 128-139.	11.4	223
79	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nature Reviews Nephrology, 2019, 15, 45-59.	9.6	330
80	Rituximab Exhibits Altered Pharmacokinetics in Patients With Membranous Nephropathy. Annals of Pharmacotherapy, 2019, 53, 357-363.	1.9	30
81	CKD Due to a Novel Mitochondrial DNA Mutation: A Case Report. American Journal of Kidney Diseases, 2019, 73, 273-277.	1.9	6
82	Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. Rheumatology, 2018, 57, 639-650.	1.9	20
83	Disease Progression and End-Stage Renal Disease in Diverse Glomerulopathies. Mayo Clinic Proceedings, 2018, 93, 133-135.	3.0	3
84	Global glomerulosclerosis with nephrotic syndrome; the clinical importance of ageÂadjustment. Kidney International, 2018, 93, 1175-1182.	5.2	39
85	Clinical and pathological phenotype of genetic causes of focal segmental glomerulosclerosis in adults. CKJ: Clinical Kidney Journal, 2018, 11, 179-190.	2.9	55
86	Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach. Journal of the American Society of Nephrology: JASN, 2018, 29, 759-774.	6.1	186
87	C3 glomerulopathy associated with monoclonal IgÂis a distinct subtype. Kidney International, 2018, 94, 178-186.	5.2	77
88	Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft. Kidney International, 2018, 94, 159-169.	5.2	49
89	Treatment of primary membranous nephropathy: where are we now?. Journal of Nephrology, 2018, 31, 489-502.	2.0	14
90	DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis. Kidney International Reports, 2018, 3, 56-64.	0.8	109

#	Article	IF	Citations
91	SP003GENETIC TESTING IN SUSPECTED HEREDITARY PROTEINURIC KIDNEY DISEASES. Nephrology Dialysis Transplantation, 2018, 33, i346-i347.	0.7	1
92	Diagnostic Utility of Complement Serology for Atypical Hemolytic Uremic Syndrome. Mayo Clinic Proceedings, 2018, 93, 1351-1362.	3.0	17
93	Membranous Nephropathy: Approaches to Treatment. American Journal of Nephrology, 2018, 47, 30-42.	3.1	48
94	The impact of eculizumab on routine complement assays. Journal of Immunological Methods, 2018, 460, 63-71.	1.4	22
95	C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic. Mayo Clinic Proceedings, 2018, 93, 991-1008.	3.0	82
96	Cryoglobulinaemia. Nature Reviews Disease Primers, 2018, 4, 11.	30.5	143
97	The authors reply. Kidney International, 2018, 94, 632-633.	5.2	0
98	Congophilic Fibrillary Glomerulonephritis: A Case Series. American Journal of Kidney Diseases, 2018, 72, 325-336.	1.9	55
99	High-dose melphalan and autologous hematopoietic stem cell transplant in patientÂwith C3 glomerulonephritis associatedÂwith monoclonal gammopathy. Clinical Nephrology, 2018, 89, 291-299.	0.7	3
100	Characterization of C3 in C3 glomerulopathy. Nephrology Dialysis Transplantation, 2017, 32, gfw290.	0.7	29
101	Evidence from the Oxford Classification cohort supports the clinical value of subclassification ofÂfocal segmental glomerulosclerosis in IgAÂnephropathy. Kidney International, 2017, 91, 235-243.	5.2	62
102	What are we missing in the clinical trials of focal segmental glomerulosclerosis?. Nephrology Dialysis Transplantation, 2017, 32, i14-i21.	0.7	15
103	Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis. Nephrology Dialysis Transplantation, 2017, 32, i139-i145.	0.7	59
104	C3 glomerulonephritis with a severe crescentic phenotype. Pediatric Nephrology, 2017, 32, 1625-1633.	1.7	15
105	A proposal for standardized grading of chronic changes in native kidney biopsy specimens. Kidney International, 2017, 91, 787-789.	5.2	161
106	Thrombotic microangiopathy associated with monoclonal gammopathy. Kidney International, 2017, 91, 691-698.	5.2	78
107	C4 Nephritic Factors in C3 Glomerulopathy: A Case Series. American Journal of Kidney Diseases, 2017, 70, 834-843.	1.9	45
108	Persistent Microscopic Hematuria as a Risk Factor for Progression of IgA Nephropathy: New Floodlight on a Nearly Forgotten Biomarker. Journal of the American Society of Nephrology: JASN, 2017, 28, 2831-2834.	6.1	33

#	Article	IF	Citations
109	The Authors Reply. Kidney International, 2017, 92, 517.	5.2	0
110	The Incidence of Primary vs Secondary Focal Segmental Glomerulosclerosis: A Clinicopathologic Study. Mayo Clinic Proceedings, 2017, 92, 1772-1781.	3.0	39
111	Treatment of membranous nephropathy: time for a paradigm shift. Nature Reviews Nephrology, 2017, 13, 563-579.	9.6	117
112	A Proposal for a Serology-Based Approach to Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2017, 28, 421-430.	6.1	273
113	Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. Journal of Renal Injury Prevention, 2017, 6, 18-25.	0.2	32
114	Familial antiglomerular basement membrane disease in zero human leukocyte antigen mismatch siblings. Clinical Nephrology, 2017, 88, 277-283.	0.7	7
115	Spectrum of manifestations of monoclonal gammopathy-associated renal lesions. Current Opinion in Nephrology and Hypertension, 2016, 25, 127-137.	2.0	57
116	Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes. Arthritis and Rheumatology, 2016, 68, 1467-1476.	5.6	94
117	Recurrent Light Chain Proximal Tubulopathy in a KidneyÂAllograft. American Journal of Kidney Diseases, 2016, 68, 483-487.	1.9	14
118	Recurrent Membranous Nephropathy After Kidney Transplantation. Transplantation, 2016, 100, 2710-2716.	1.0	69
119	Leishmaniasis-Associated Membranoproliferative Glomerulonephritis With Massive Complement Deposition. Kidney International Reports, 2016, 1, 125-130.	0.8	6
120	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. American Journal of Hematology, 2016, 91, 1123-1128.	4.1	76
121	ANCA-associated vasculitis â€" clinical utility of using ANCA specificity to classify patients. Nature Reviews Rheumatology, 2016, 12, 570-579.	8.0	219
122	Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. Mayo Clinic Proceedings, 2016, 91, 1189-1211.	3.0	55
123	Clinical, biopsy, and mass spectrometry characteristics of renal apolipoprotein A-IVÂamyloidosis. Kidney International, 2016, 90, 658-664.	5.2	42
124	Manifestations of Complement-Mediated and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. Ophthalmology, 2016, 123, 1588-1594.	5.2	19
125	C4d as a marker for masked immune deposits. Kidney International, 2016, 90, 223-224.	5.2	7
126	Diagnosis of complement alternative pathway disorders. Kidney International, 2016, 89, 278-288.	5.2	74

#	Article	IF	Citations
127	Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 1290-1295.	0.7	9
128	Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease. Pediatric Nephrology, 2016, 31, 683-687.	1.7	12
129	The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis. Kidney International, 2016, 89, 897-908.	5.2	95
130	Rapidly progressive glomerulonephritis due to coexistent anti-glomerular basement membrane disease and fibrillary glomerulonephritis. CKJ: Clinical Kidney Journal, 2016, 9, 97-101.	2.9	9
131	C4 Glomerulopathy: A Disease Entity Associated WithÂC4dÂDeposition. American Journal of Kidney Diseases, 2016, 67, 949-953.	1.9	23
132	C3 glomerulonephritis and autoimmune disease: more than a fortuitous association?. Journal of Nephrology, 2016, 29, 203-209.	2.0	18
133	C3 Glomerulonephritis Associated With Complement Factor B Mutation. American Journal of Kidney Diseases, 2015, 65, 520-521.	1.9	10
134	Con: Biomarkers in glomerular diseases: putting the cart before the wheel?. Nephrology Dialysis Transplantation, 2015, 30, 885-890.	0.7	6
135	Overlap of ultrastructural findings in C3 glomerulonephritis and dense deposit disease. Kidney International, 2015, 88, 1449-1450.	5.2	7
136	Diagnosis of monoclonal gammopathy of renal significance. Kidney International, 2015, 87, 698-711.	5.2	339
137	Advances in basic science and translational medicine. Nature Reviews Nephrology, 2015, 11, 67-68.	9.6	2
138	Hematologic Characteristics of Proliferative Glomerulonephritides With Nonorganized Monoclonal Immunoglobulin Deposits. Mayo Clinic Proceedings, 2015, 90, 587-596.	3.0	92
139	A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR). Nephron, 2015, 130, 159-168.	1.8	49
140	Bortezomib-induced acute interstitial nephritis. Nephrology Dialysis Transplantation, 2015, 30, 1225-1229.	0.7	25
141	Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway. Journal of the American Society of Nephrology: JASN, 2015, 26, 2917-2929.	6.1	84
142	Histiocytic glomerulopathy associated with macrophage activation syndrome. CKJ: Clinical Kidney Journal, 2015, 8, 157-160.	2.9	11
143	C4d as a Diagnostic Tool in Proliferative GN. Journal of the American Society of Nephrology: JASN, 2015, 26, 2852-2859.	6.1	106
144	IgD Heavy-Chain Deposition Disease. Journal of the American Society of Nephrology: JASN, 2015, 26, 784-790.	6.1	35

#	Article	IF	Citations
145	Opponent's comments. Nephrology Dialysis Transplantation, 2015, 30, 898-899.	0.7	1
146	Nephrotic syndrome redux. Nephrology Dialysis Transplantation, 2015, 30, 12-17.	0.7	30
147	Focal segmental glomerulosclerosis: towards a better understanding for the practicing nephrologist. Nephrology Dialysis Transplantation, 2015, 30, 375-384.	0.7	81
148	Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement. Journal of the American Society of Nephrology: JASN, 2015, 26, 976-985.	6.1	137
149	Novel Genetic Variants in Complement-Mediated Thrombotic Microangiopath. Blood, 2015, 126, 1050-1050.	1.4	3
150	A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P.) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 547 Transplantation, 2014, 29, 1570-1577.	0.7	92
151	American Society of Nephrology Quiz and Questionnaire 2013. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 987-996.	4.5	0
152	Frequent-relapsing, steroid-dependent minimal change disease: is rituximab the answer?. Nephrology Dialysis Transplantation, 2014, 29, 722-727.	0.7	7
153	Does tonsillectomy have a role in the treatment of patients with immunoglobulin A nephropathy?. Nephrology Dialysis Transplantation, 2014, 29, 1456-1459.	0.7	14
154	Pathology of Renal Diseases Associated with Dysfunction of the Alternative Pathway of Complement: C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome (aHUS). Seminars in Thrombosis and Hemostasis, 2014, 40, 416-421.	2.7	61
155	Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis. Therapeutic Advances in Musculoskeletal Disease, 2014, 6, 58-74.	2.7	8
156	Focal and segmental glomerulosclerosis: clinical and kidney biopsy correlations. CKJ: Clinical Kidney Journal, 2014, 7, 531-537.	2.9	60
157	Treatment of ANCA-Associated Vasculitis: New Therapies and a Look at Old Entities. Advances in Chronic Kidney Disease, 2014, 21, 182-193.	1.4	6
158	Histologic classification of glomerular diseases: clinicopathologic correlations, limitations exposed by validation studies, and suggestions for modification. Kidney International, 2014, 85, 779-793.	5.2	54
159	Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis. New England Journal of Medicine, 2013, 369, 417-427.	27.0	611
160	Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2013, 72, 1342-1350.	0.9	109
161	C3 Glomerulonephritis Associated With Monoclonal Gammopathy: A Case Series. American Journal of Kidney Diseases, 2013, 62, 506-514.	1.9	150
162	Refining phenotypes in ANCA-associated vasculitis. Nature Reviews Nephrology, 2013, 9, 6-8.	9.6	5

#	Article	IF	Citations
163	A Patient with Nephrotic-Range Proteinuria and Focal Global Glomerulosclerosis. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1979-1987.	4.5	24
164	Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney International, 2013, 83, 749-756.	5.2	268
165	American Society of Nephrology Quiz and Questionnaire 2012. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1460-1465.	4.5	5
166	Idiopathic membranoproliferative glomerulonephritis: does it exist?. Nephrology Dialysis Transplantation, 2012, 27, 4288-4294.	0.7	51
167	Membranoproliferative Glomerulonephritis â€" A New Look at an Old Entity. New England Journal of Medicine, 2012, 366, 1119-1131.	27.0	442
168	Association of a Novel Complement Factor H Mutation With Severe Crescentic and Necrotizing Glomerulonephritis. American Journal of Kidney Diseases, 2012, 60, 126-132.	1.9	31
169	Rituximab in ANCA-Associated Vasculitis: Fad or Fact?. Nephron Clinical Practice, 2011, 118, c182-c188.	2.3	10
170	IgG4-Related Tubulointerstitial Nephritis With Membranous Nephropathy. American Journal of Kidney Diseases, 2011, 58, 320-324.	1.9	42
171	Rituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2011, 22, 1543-1550.	6.1	403
172	Dense Deposit Disease Associated With Monoclonal Gammopathy of Undetermined Significance. American Journal of Kidney Diseases, 2010, 56, 977-982.	1.9	107
173	Rituximab Therapy in Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2188-2198.	4.5	247
174	Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. New England Journal of Medicine, 2010, 363, 221-232.	27.0	2,275
175	Membranoproliferative Glomerulonephritis Secondary to Monoclonal Gammopathy. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 770-782.	4.5	156
176	Renal involvement in Neimann-Pick Disease. CKJ: Clinical Kidney Journal, 2009, 2, 448-451.	2.9	15
177	Induction of Heme Oxygenase-1 and Ferritin in the Kidney in Warm Antibody Hemolytic Anemia. American Journal of Kidney Diseases, 2008, 52, 972-977.	1.9	33
178	Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 905-919.	4.5	126
179	Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease. Biologics: Targets and Therapy, 2008, 2, 823.	3.2	21
180	Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrology Dialysis Transplantation, 2004, 19, 1288-1292.	0.7	104

#	Article	IF	Citations
181	Henoch-Schonlein purpura nephritis. International Journal of Dermatology, 2003, 42, 170-177.	1.0	52
182	Membranous Nephropathy. , 0, , 158-169.		0